Veterinary Parasitology, Liverpool School of Tropical Medicine/Faculty of Veterinary Science, University of Liverpool, Pembroke Place, Liverpool, UK.
Parasit Vectors. 2008 Jun 20;1(1):18. doi: 10.1186/1756-3305-1-18.
Human onchocerciasis or river blindness, caused by the filarial nematode Onchocerca volvulus, is currently controlled using the microfilaricidal drug, ivermectin. However, ivermectin does not kill adult O. volvulus, and in areas with less than 65% ivermectin coverage of the population, there is no effect on transmission. Therefore, there is still a need for a macrofilaricidal drug. Using the bovine filarial nematode O. ochengi (found naturally in African cattle), the macrofilaricidal efficacy of the modified flubendazole, UMF-078, was investigated.
Groups of 3 cows were treated with one of the following regimens: (a) a single dose of UMF-078 at 150 mg/kg intramuscularly (im), (b) 50 mg/kg im, (c) 150 mg/kg intraabomasally (ia), (d) 50 mg/kg ia, or (e) not treated (controls).
After treatment at 150 mg/kg im, nodule diameter, worm motility and worm viability (as measured by metabolic reduction of tetrazolium to formazan) declined significantly compared with pre-treatment values and concurrent controls. There was abrogation of embryogenesis and death of all adult worms by 24 weeks post-treatment (pt). Animals treated at 50 mg/kg im showed a decline in nodule diameter together with abrogated reproduction, reduced motility, and lower metabolic activity in isolated worms, culminating in approximately 50% worm mortality by 52 weeks pt. Worms removed from animals treated ia were not killed, but exhibited a temporary embryotoxic effect which had waned by 12 weeks pt in the 50 mg/kg ia group and by 24 weeks pt in the 150 mg/kg ia group. These differences could be explained by the different absorption rates and elimination half-lives for each dose and route of administration.
Although we did not observe any signs of mammalian toxicity in this trial with a single dose, other studies have raised concerns regarding neuro- and genotoxicity. Consequently, further evaluation of this compound has been suspended. Nonetheless, these results validate the molecular target of the benzimidazoles as a promising lead for rational design of macrofilaricidal drugs.
由旋毛形线虫引起的人体盘尾丝虫病或河盲症,目前采用米尔贝肟(ivermectin)这一杀微丝蚴药物进行控制。然而,米尔贝肟并不能杀死成年旋毛形线虫,而且在人群中伊维菌素覆盖率低于 65%的地区,对传播也没有影响。因此,仍然需要一种杀成虫药物。本研究利用天然存在于非洲牛体内的牛盘尾丝虫,对改良型氟苯达唑(UMF-078)的杀成虫疗效进行了研究。
每组 3 头牛分别接受以下方案中的一种治疗:(a)肌内注射 150mg/kg 的 UMF-078(im);(b)im 注射 50mg/kg;(c)abomasal 注射 150mg/kg;(d)ia 注射 50mg/kg;(e)不治疗(对照组)。
肌内注射 150mg/kg 后,与治疗前和同时期对照组相比,结节直径、虫体运动能力和虫体活力(通过四唑氮还原形成甲臜的代谢减少来衡量)显著下降。治疗后 24 周,所有成虫死亡,胚胎发生中止。im 注射 50mg/kg 的动物,结节直径下降,生殖能力丧失,虫体运动能力降低,代谢活性降低,治疗后 52 周,虫体死亡率约为 50%。ia 注射的虫体未被杀死,但表现出暂时的胚胎毒性,在 50mg/kg ia 组中,12 周时毒性减弱,在 150mg/kg ia 组中,24 周时毒性减弱。这些差异可以用不同剂量和给药途径的不同吸收速率和消除半衰期来解释。
尽管我们在单次剂量试验中没有观察到任何哺乳动物毒性迹象,但其他研究对其神经毒性和遗传毒性表示担忧。因此,对该化合物的进一步评估已被暂停。尽管如此,这些结果验证了苯并咪唑类药物的分子靶标是合理设计杀成虫药物的一个有前途的先导。